Mymetics HIV Vaccine Shows Strong Preliminary Phase I Data

Epalinges, Switzerland, 30 November 2010

Mymetics Corporation (OTCBB: MYMX), a pioneer in the development of vaccines preventing mucosal transmission of human infectious diseases, announced today strong preliminary results of a Phase I trial on its promising HIV vaccine, MYMV101. Unlike most current vaccines, seeking to eliminate pathogens once they have already entered the bloodstream, Mymetics’ vaccines are designed to block early transmission and infection events, preventing virus from settling and spreading within the body. This represents a highly promising but, until now, poorly investigated approach to preventing HIV infection.

Media Name Media Type Description Download
101130 Mymetics Final Press Release Phase I preliminary data PDF Download